Calibr-Skaggs Institute for Innovative Medicines

We are excited to announce that we are now Calibr-Skaggs Institute for Innovative Medicine, and we remain a division of Scripps Research. Press release: https://lnkd.in/e6DRe2fA We are also excited to announce our new website! Please have a look: https://lnkd.in/gjHU84zA #nonprofit #drugdevelopment #pipeline

Calibr-Skaggs is on the lookout for an exceptionally talented Associate Director to lead our protein sciences team within the biologics drug discovery group. If you have a passion for innovation and leadership, this is your chance to make a significant impact in the field of drug discovery! Join us in pioneering advancements in immuno-oncology, immunology, infectious and neglected tropical diseases, metabolic disorders, neuro, and rare disease indications. Ready to take the lead in groundbreaking research? Apply now at Calibr-Skaggs! https://lnkd.in/gPHgsdYG #DrugDiscovery #Leadership #Innovation #ProteinSciences #CareerOpportunity

A new study published in Science Magazine, led by Scripps Research Prof. John Teijaro, PhD, has discovered a powerful combination therapy that boosts the effectiveness of cancer treatments. The team found that combining ruxolitinib, an approved immunosuppressive drug, with checkpoint inhibitors supercharges T-cell responses. “It's very rare to have supporting evidence with preclinical data and a clinical trial in one paper,” says Teijaro. “Our results are particularly exciting because we are already seeing patients benefit from the combination and we believe this could be applied to several immunotherapy resistant cancers.” Read the full press release: https://ow.ly/tbEK50SmNsL

Following last week’s announcement of MMV’s 2023 Project of the Year, a novel compound that holds the potential to cure patients, prevent infections and counter drug resistance, we sat down with the two project leads from MMV and Calibr-Skaggs Institute for Innovative Medicines to learn more about their process, how partnering across organizations can facilitate drug development and more.    Read the entire interview with Calibr-Skaggs’ Director of Medical Chemistry, Dr Anil Gupta, and MMV’s Senior Director of Drug Discovery, Dr James Duffy: bit.ly/MMV_PoY 

This week, MMV’s Expert Scientific Advisory Committee (ESAC) awarded the 2023 Project of the Year to a discovery team led by Dr Anil Gupta, Director of Medical Chemistry for the Calibr-Skaggs Institute for Innovative Medicines and Dr James Duffy, Senior Director of Drug Discovery for MMV.    The award recognizes the team’s discovery of CMQ069, a compound that may help expand the antimalarial toolbox, thanks to its potency on multiple stages of the malaria parasite lifecycle. As a novel compound with potential for low-dose treatment, CMQ069 could provide an alternative to the current artemisinin-based therapies for which partial drug resistance has been detected in Asia and more recently in Africa. CMQ069 may also have the capacity to meet the oral chemoprevention goal of protective efficacy following a single monthly oral dose.     Congratulations to Dr Anil Gupta, Dr Arnab Chatterjee, Dr Case McNamara, Dr Jenya (Yevgeniya) Antonova-Koch and Dr Peter Schultz from the project team at Calibr-Skaggs, and Dr James Duffy, Dr Anne Cooper and Dr Peter Webborn at MMV for this recognition of scientific excellence!    Learn more about this project and the CMQ069 compound: bit.ly/MMV_PoY24 

We're excited to share that the Medicines for Malaria Venture has awarded the 2023 Project of the Year to the Calibr-Skaggs Institute for Innovative Medicines! https://lnkd.in/e_wD3ibJ This prestigious recognition highlights the groundbreaking efforts in malaria research and drug development led by our exceptional team members, Anil Gupta, Case McNamara, and Arnab Chatterjee. Their dedication and innovative approach have been instrumental in advancing our mission to combat malaria and improve global health. Congratulations to the entire team for this well-deserved honor! #globalhealth #drugdiscovery #award

Congratulations to Scripps Research President and CEO Peter Schultz, PhD, on receiving the prestigious 2024 AIC Gold Medal from the American Institute of Chemists (AIC) for his significant contributions to chemical and synthetic biology. Schultz’s work has led to the expansion of the genetic code of living organisms, the discovery of catalytic antibodies, and the development and application of molecular diversity technologies to address problems in chemistry, materials science, and medicine. Learn more: https://ow.ly/Ra1y50RAJEO

A team of scientists at Scripps Research and the Calibr-Skaggs Institute for Innovative Medicines has developed a lung-targeted, druglike small molecule to stimulate the growth of lung stem cells. Their PNAS study, led by Peter G. Schultz, PhD, President and CEO of Scripps Research, and Associate Professor Michael Bollong, PhD, provides a biological proof of concept for CMR316—Calibr-Skaggs’ therapy designed for idiopathic pulmonary fibrosis (IPF). Learn more about CMR316 and its upcoming phase 1 clinical trial this summer: https://ow.ly/qA5j50RcA14

Congratulations to Associate Professor Michael Bollong, on receiving the David W. Robertson Award for Excellence in Medicinal Chemistry from the ACS Division of Medicinal Chemistry. This recognition highlights Bollong's remarkable contributions to drug discovery and regenerative medicine. The award, supported by Pfizer Inc. and named in memory of the esteemed chemist David W. Robertson, showcases Bollong's innovative work at Scripps Research. His research focuses on identifying new therapeutics targeting regeneration and cell stress signaling pathways, aiming to enhance medical science and improve patient outcomes.

We're #hiring a new RESEARCH SCIENTIST or RESEARCH ASSOCIATE, Molecular Biology in La Jolla, California. Apply today or share this post with your network.